Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry

Forensic Toxicology

Volumn 33, Issue 2, 2015, Pages 295-310

  Castaneto, Marisol S ^a,b   Wohlfarth, Ariane ^a   Pang, Shaokun ^c   Zhu, Mingshe ^d   Scheidweiler, Karl B ^a   Kronstrand, Robert ^e   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c MDS SCIEX   (Canada)

^d BRISTOL MYERS SQUIBB   (United States)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

AB FUBINACA; Hepatocytes; HRMS; In silico; Metabolite profiling

Indexed keywords

CANNABINOID; CARBOXYLIC ACID; DRUG METABOLITE; N (1 AMINO 3 METHYL 1 OXOBUTAN 2 YL) 1 (4 FLUOROBENZYL) 1H INDAZOLE 3 CARBOXAMIDE; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DEFLUORINATION; DEHYDROGENATION; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MASS SPECTROMETRY; MICROSOME; PREVALENCE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 84937523344     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-015-0275-8     Document Type: Article

References (33)

1. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41
2. United Nations on Drugs and Crime. World Drug Report 2014 (2014) United Nations: Vienna.http://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf. Accessed Dec 2014
3. US Drug Enforcement Administration (2013) Establishment of drug codes for 26 substances. Final rule. Fed Regist 78:664–666
4. Buchler JP, Hayes MJ, Hegde SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK (2009) Indazole derivatives. US Patent CA 2714573 A1:1–283
5. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH -018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6:e21917
6. Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (2013) New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-caboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol 31:93–100
7. Drug Enforcement Administration (2014) 2013 Midyear Report. Department of Justice, Springfield, VA. http: http://www.deadiversion.usdoj.gov/nflis/2013midyear.pdf. Accessed Aug 2014
8. Drug Enforcement Administration (2014) Schedules of controlled substances: temporary placement of four synthetic cannabinoids into schedule I: notice of intent. Fed Regist 79:7577–7582
9. Centers for Disease Control and Prevention (2013) Notes from the field: severe illness associated with synthetic cannabinoid use—Brunswick, Georgia, 2013. MMWR Morb Mortal Wkly Rep 62:939
10. Federal Drug Control Service of Russia (2014) Bыcтyплeниe пpeдceдaтeля ГAК, диpeктopa ФCКH Poccии B.П. Ивaнoвa нa зaceдaнии ГAК 6 oктябpя 2014 г. http://fskn.gov.ru/includes/periodics/speeches_fskn/2014/1006/124332682/detail.shtml. Accessed Dec 2014
11. Gurney SMR, Scott KS, Kacinko SL, Presley BC, Logan BK (2014) Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 26:53–78
12. Research Chemical Review (2014) Trip report tme: 250 mg AB-FUBINACA and 500 mg AH-7921. http://researchchemicalreview.wordpress.com/2014/02/25/trip-report-tme-250mg-ab-fubinaca-and-500mg-ah-7921/ Accessed Aug 2014
13. De Brabanter N, Esposito S, Tudela E, Lootens L, Meuleman P, Leroux-Roels G, Deventer K, Van Eenoo P (2013) In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun Mass Spectrom 27:2115–2126
14. Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V (2011) Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B 879:2519–2526
15. Wintermeyer A, Moller I, Thevis M, Jubner M, Beike J, Rothschild MA, Bender K (2010) In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 398:2141–2153
16. Takayama T, Suzuki M, Todoroki K, Inoue K, Min JZ, Kikura-Hanajiri R, Goda Y, Toyo’oka T (2014) UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and alpha-PVT, by human liver microsomes. Biomed Chromatogr 28:831–838
17. Jang M, Shin I, Yang W, Chang H, Yoo HH, Lee J, Kim E (2014) Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake. Forensic Sci Int 244:85–91
18. Holm NB, Pedersen AJ, Dalsgaard PW, Linnet K (2015) Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test Anal 7:199–206
19. Jin MJ, Lee J, In MK, Yoo HH (2013) Characterization of in vitro metabolites of CP 47,497, a synthetic cannabinoid, in human liver microsomes by LC–MS/MS. J Forensic Sci 58:195–199
20. Gandhi AS, Wohlfarth AW, Zhu M, Pang S, Castaneto M, Scheidweiler KB, Huestis MA (2015) High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Test Anal 7:187–198
21. Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, Huestis MA (2013) First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J 15:1091–1098
22. Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA (2014) Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem 406:1763–1780
23. Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Huestis MA (2014) Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis 6:1187–2000
24. Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, Huestis MA (2013) First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem 59:1638–1648
25. Strano-Rossi S, Anzilotti L, Dragoni S, Pellegrino RM, Goracci L, Pascali VL, Cruciani G (2014) Metabolism of JWH-015, JWH-098, JWH-251, and JWH-307 in silico and in vitro: a pilot study for the detection of unknown synthetic cannabinoids metabolites. Anal Bioanal Chem 406:3621–3636
26. Thomsen R, Nielsen LM, Holm NB, Rasmussen HB, Linnet K (2014) Synthetic cannabimimetic agents metabolized by carboxylesterases. Drug Test Anal. doi:10.1002/dta.1731
27. Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H (2006) Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 58:453–472
28. McNaney CA, Drexler DM, Hnatyshyn SY, Zvyaga TA, Knipe JO, Belcastro JV, Sanders M (2008) An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. ASSAY Drug Dev Technol 6:121–129
29. Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D, Coassolo P (1997) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 14:152–155
30. Sobolevsky T, Prasolov I, Rodchenkov G (2012) Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 4:745–753
31. Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, Park DK (2010) Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos 31:367–395
32. Castaneto MS, Scheidweiler KB, Gandhi A, Wohlfarth A, Klette KL, Martin TM, Huestis MA (2014) Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. Drug Test Anal. doi:10.1002/dta.1709
33. Hutter M, Broecker S, Kneisel S, Auwarter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC-MS/MS techniques. J Mass Spectrom 47:54–65